Search

Displaying results 5211 - 5220 of 5504 in total
  1. Drug

    Octacosanol

    go.drugbank.com/drugs/DB11220
    InvestigationalNutraceutical

    It has been studied as a potential therapeutic agent for the treatment of Parkinson's disease.

  2. Drug

    PDPSC18

    go.drugbank.com/drugs/DB05167
    Experimental

    PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.

  3. Drug

    ENMD-1198

    go.drugbank.com/drugs/DB05959
    Experimental

  4. Drug

    Oral Polio Vaccine

    go.drugbank.com/drugs/DB15864
    Investigational

    The oral polio vaccine (OPV) is a live attenuated vaccine containing a mixture of one or more strains of poliovirus serotypes. Strains of the virus are selected based on their reduced incidence of spreading to the central nervous system ...

  5. Drug

    Cobamamide

    go.drugbank.com/drugs/DB11191
    ApprovedNutraceutical

    It is therefore important to treat vitamin B12 deficiency with a combination of MeCbl and AdCbl or hydroxocobalamin or cobalamin [L2054].

  6. Drug

    Osemozotan

    go.drugbank.com/drugs/DB05339
    Experimental

    MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).

  7. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. AME-527 was generated by protein engineering and identified from a library of antibody variants based on its impr...

  8. Drug

    Telcagepant

    go.drugbank.com/drugs/DB12228
    Investigational

    It is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine.

  9. Drug

    Brilaroxazine

    go.drugbank.com/drugs/DB09226
    Investigational

    As of May 2015, it is in phase III clinical trials for schizophrenia.

  10. Drug

    CoVac-1

    go.drugbank.com/drugs/DB16429
    Investigational

    T-cell immunity[A226588]. … Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588].